Intestinal alkaline phosphatase at the crossroad of intestinal health and disease - a putative role in type 1 diabetes.
M I LasseniusC L FogartyM BlautK HaimilaL RiittinenA PajuJ KirveskariJ JärveläA J AholaD GordinM-A HärmaA KumarS R HamarnehR A HodinT SorsaT TervahartialaS HörkköP J PussinenC ForsblomM JauhiainenM-R TaskinenP-H GroopMarkku Lehtonull nullPublished in: Journal of internal medicine (2017)
Deprivation of protective intestinal factors may increase the risk of inflammation in the gut - a phenomenon that seems to be present already in patients with uncomplicated type 1 diabetes. Low levels of intestinal IgA and antibodies to oxidized lipid epitopes may predispose such patients to inflammation-driven complications such as cardiovascular disease and diabetic nephropathy. Importantly, oral IAP supplementation could have beneficial therapeutic effects on gut metabolic homeostasis, possibly through stimulation of intestinal IgA secretion.
Keyphrases
- type diabetes
- cardiovascular disease
- diabetic nephropathy
- oxidative stress
- end stage renal disease
- healthcare
- ejection fraction
- chronic kidney disease
- newly diagnosed
- public health
- mental health
- glycemic control
- prognostic factors
- peritoneal dialysis
- skeletal muscle
- risk assessment
- health information
- patient reported outcomes
- coronary artery disease
- human health
- weight loss
- fatty acid
- urinary tract infection